Third Quarter 2023 Financial Results and Business Update November 8, 2023 Non-GAAP financial information 2 This presentation and the discussions during this conference call include certain financial measures that were not prepared in accordance with accounting principles generally accepted in the U.S. (GAAP), including adjusted net income, adjusted diluted earnings per share, revenue growth at constant currency, which excludes the impact of changes in foreign exchange rates and hedging gains or losses, and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ☒ ACT OF 1934 For the quarterly period ended September 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ☐ ACT OF 1934 Commission File Number 0-19311 BIOGEN INC. (Exact name of registrant as specified in its charter) Delaware 33-0112644 (State or other jurisdiction of (I.R.S. Employer incorporation or organization ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_46921327927c3961972b05973647ef78.html ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_39fb145b14bb34d269cb7bca92bdff40.html ...

Biogen Inc. (NASDAQ:BIIB) Q2 2023 Earnings Conference Call July 25, 2023 8:00 AM ET Company Participants Chuck Triano - Head of Investor Relations Christopher Viehbacher - President and Chief Executive Officer Priya Singhal - Head of Development and Interim Head of Research Michael McDonnell - Chief Financial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Marc Goodman - Leerink Partners Robyn Karnauskas - Truist Securities Mohit Bansal - Wells Fargo Umer Raffat - Evercore ISI Salv ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ☒ ACT OF 1934 For the quarterly period ended June 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ☐ ACT OF 1934 Commission File Number 0-19311 BIOGEN INC. (Exact name of registrant as specified in its charter) Delaware 33-0112644 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Ide ...

First Quarter 2023 Financial Results and Business Update Non-GAAP financial information This presentation and the discussions during this conference call include certain financial measures that were not prepared in accordance with accounting principles generallyaccepted in the U.S. (GAAP), including adjusted net income, adjusted diluted earnings per share, revenue growth at constant currency, which excludes the impact of changes in foreign exchange rates and hedging gains or losses, and free cash flow, whic ...

Biogen Inc. (NASDAQ:BIIB) Q1 2023 Earnings Conference Call April 25, 2023 8:00 AM ET Company Participants Chuck Triano - Head of Investor Relations Christopher Viehbacher - President and Chief Executive Officer Priya Singhal - Head of Development and Interim Head of Research and Global Safety and Regulatory Sciences Michael McDonnell - Chief Financial Officer Conference Call Participants Phil Nadeau - TD Cowen Paul Matteis - Stifel Geoff Meacham - Bank of America Salveen Richter - Goldman Sachs Umer Raffat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ☒ ACT OF 1934 For the quarterly period ended March 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ☐ ACT OF 1934 Commission File Number 0-19311 BIOGEN INC. (Exact name of registrant as specified in its charter) Delaware 33-0112644 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Id ...

Call Start: 09:50 January 1, 0000 10:20 AM ET Biogen Inc. (NASDAQ:BIIB) 43rd Annual Cowen Healthcare Conference Call March 6, 2023 09:50 ET Company Participants Christopher Viehbacher - Chief Executive Officer Conference Call Participants Philip Nadeau - Cowen & Company Philip Nadeau Welcome to the TD Cowen 43rd Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analyst here at Cowen. It's my pleasure to moderate a fireside chat with Biogen. We're really happy to have with us today, Chris Vie ...